Opening of United States, East Coast Headquarters

Connecticut site features a learning centre and fully equipped training laboratory to provide on-site immersive, didactic ex-vivo, training sessions supporting Creo’s education led commercialisation strategy

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it has opened its United States headquarters at the Summit, Danbury, Connecticut, USA.

The space is designed to support Creo’s global growth and focus in the key United States market and features a learning centre and a fully equipped laboratory for clinical development and training purposes which will support Creo’s education led commercialisation strategy and enable healthcare providers to participate in immersive, didactic ex-vivo training sessions. United States customer service, finance, product logistics, distribution and other day-to-day functions will also be based in the Danbury, Connecticut, office. Located, northeast of New York city, the office’s proximity to international airports provides convenient access for visiting clinicians and members of staff.

Over the past 18 months, Creo has established a direct commercial team in the United States, led by experienced and successful leaders in market development. The Company also has a US Director of Clinical Education, assisted by Clinical Support Specialists, responsible for ensuring safe and effective use of our product platform and devices.

Creo’s CROMA Energy Generator platform is in place at multiple academic institutions across the United States, with key opinion leaders trained through Creo’s Clinical Education Programme. These centres have treated our first patients in the United States and have been identified as “Centres of Excellence for the operation of our Clinical Education Programme.” They will be key training sites to educate the second wave of United States clinical users. We intend to increase the number of United States installations and training centres to support the scaling of our presence in the United States.

Craig Gulliford, Chief Executive Officer of Creo, commented:

We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key United States Market. These new premises will provide an excellent working environment for our United States team and a platform to attract further talent in this key region of the United States market.

David Woods, Chief Commercial Officer of Creo, commented:

Since my appointment in August last year, I have been busy assembling an experienced team to help capitalise on our continued evolution and expansion as a leading medical device Company. The opening of this clinical training and commercial support facility in the United States represents the next phase in our planned and sustained development and further illustrates our growth and focus in the United States region, which gives even greater access to another important market.

Posted 07/16/21

For press enquiries please contact For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities


05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch


01 November 2023

Speedboat® UltraSlim: US FDA Clearance


25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months


12 September 2023

Half Year Report: H1-2023


19 June 2023

Speedboat Inject cleared for upper GI use in Europe


01 June 2023

Speedboat™ Inject selected by NICE for assessment